News and Trends 29 Mar 2017 French Gene Therapy Biotech Gets Ready for Phase II/III …French biotech specializing in gene therapy of rare CNS diseases. Its lead asset is a gene therapy for the treatment of the rare genetic disorder Sanfilippo A. This disease severely… March 29, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
In Depth 23 Apr 2025 The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval …an obstacle in the treatment of central nervous system (CNS) disorders. Big pharma leading the way in the development of BTK inhibitors for multiple sclerosis It is fair to say… April 23, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 Apr 2024 Eight biotech companies you should know about in Austria …that can be used to test treatments for neuropsychiatric disorders. The organoids are designed to carry out high-throughput screening of drugs targeting the central nervous system (CNS). It merges cell… April 9, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Apr 2024 Seven biotech companies climbing their way up in Colorado …ELVN-002 is a highly selective, HER2 inhibitor that can penetrate through the central nervous system (CNS), and target HER2-positive cancers like breast cancer, non-small cell lung cancer (NSCLC), and colorectal… April 16, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Top biotech grants and campaigns …Additives and Technologies Temperature as an Indicator of Surgical Site Infection Seeking Novel CNS Indications and Mechanistic Pathways for RIPK1 Inhibition Seeking Late Preclinical Oncology Assets: Small Molecules with IND-enabling… June 20, 2024 - 2 minutesmins - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Dec 2017 Bored Between the Holidays? Watch these Biotech Videos! …the industry. He told us more about the company’s strategy through the example of its partnership with Oxford, Lab282. (Read the summary here) Will RNA treat CNS disorders next? RNA… December 28, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 14 Sep 2017 New Dutch Spin Out will Treat Stroke with RNA Therapy …in Leiden, Amylon will focus on the development of therapies for central nervous system (CNS) disorders, with an exclusive license to develop therapeutics for beta amyloid-related disorders granted by ProQR,… September 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jun 2025 Pushing biotech forward in France: 18 companies to know about …drug discovery expertise with Cilcare’s specialized knowledge in auditory disorders. Coave Therapeutics Founded: 2015 Headquarters: Paris, France Focus: Gene therapies for ocular and central nervous system (CNS) diseases Coave Therapeutics… June 10, 2025 - 16 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Jul 2025 Seven biotechs in Belgium making leaps in the clinic …system (CNS). Last year in July, it nabbed €60 million ($70.14 million) in a series B funding round to further advance its GPCR pipeline. Galapagos Founded: 1999 Focus area: Cell… July 22, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 IRLAB’s partner Ipsen starts mesdopetam clinical studies …potential to prevent the development of dyskinesia. About IRLAB IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam and… September 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 26 Feb 2025 New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis? …major inhibitory neurotransmitter in the central nervous system (CNS). Algiax said that it will now explore opportunities to support the rapid advancement of AP-325’s clinical development. Levicept reports positive phase… February 26, 2025 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2025 Vandria reports VNA-318’s first-in-human data in Alzheimer’s …Alzheimer’s clinical-development plan. That is where Vandria’s VNA‑318 emerges as novel, one of the rare small molecules designed for mitophagy-plus activity in the central nervous system (CNS), now advanced into… December 2, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email